← Back to Search

Sympathomimetic Agent

Oxymetazoline hydrochloride 0.1% ophthalmic solution for Eye Symptoms

Phase 4
Waitlist Available
Led By Wendy W. Lee, MD
Research Sponsored by University of Miami
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, day 1
Awards & highlights

Study Summary

This trial will test the effects of a new eye drop meant to improve the appearance of the eyes.

Eligible Conditions
  • Eye Symptoms
  • Pink Eye
  • Drooping Eyelid

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Palpebral Fissure Height
Secondary outcome measures
Change in Eye Redness as Measured by the Validated Bulbar Redness Grading Scale
Change in Patient-reported Eye Appearance - FACE-Q Eye Appearance
Change in Patient-reported Eye Appearance - FACE-Q Upper Eyelid Appearance

Side effects data

From 2022 Phase 4 trial • 114 Patients • NCT04831047
5%
Dry eye
5%
Eyelid heaviness
4%
Headache
2%
Light Sensitivity
100%
80%
60%
40%
20%
0%
Study treatment Arm
Upneeq Group
Control Group

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Upneeq GroupExperimental Treatment1 Intervention
Participants in this group will receive a one-time dosing of oxymetazoline hydrochloride 0.1% (1 drop applied to ocular surface of each eye of patients in the treatment group)
Group II: Control GroupPlacebo Group1 Intervention
Participants in this group will receive a one-time dosing of balanced saline solution (1 drop applied to ocular surface of each eye of patients in the control group)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oxymetazoline hydrochloride 0.1% ophthalmic solution
2021
Completed Phase 4
~120

Find a Location

Who is running the clinical trial?

University of MiamiLead Sponsor
901 Previous Clinical Trials
409,872 Total Patients Enrolled
Wendy W. Lee, MDPrincipal InvestigatorUniversity of Miami Bascom Palmer Eye Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What maladies does Oxymetazoline hydrochloride 0.1% ophthalmic solution typically address?

"Oxymetazoline hydrochloride 0.1% ophthalmic solution can be taken to relieve anesthesia, conduction, and persistent facial erythema as well as rhinorrhoea or nasal blockage."

Answered by AI

Does Oxymetazoline hydrochloride 0.1% ophthalmic solution pose any risks to human health?

"Oxymetazoline hydrochloride 0.1% ophthalmic solution, which is sanctioned by regulatory bodies, was assigned a safety score of 3 out of possible maximum rating of 3."

Answered by AI

What prior investigations have been done with Oxymetazoline hydrochloride 0.1% ophthalmic solution?

"Currently, seven medical experiments are actively investigating Oxymetazoline hydrochloride 0.1% ophthalmic solution; none of which have reached the third clinical trial stage. With 12 centres running trials for this medication, most of them situated in Raleigh, North carolina."

Answered by AI

What is the highest possible number of people included in this clinical investigation?

"At this time, no new participants are being accepted for this medical trial. The study was first published on June 8th 2021 and last updated on May 11th 2022. If you're interested in participating in other research studies, consider the 27 different trials currently recruiting patients with eye-related issues or the 7 Oxymetazoline hydrochloride 0.1% ophthalmic solution trials that require volunteers."

Answered by AI

Is this an unprecedented research endeavor?

"Presently, 7 clinical trials are occurring for Oxymetazoline hydrochloride 0.1% ophthalmic solution across 11 cities in 3 countries. The earliest of these experiments was conducted by RDD Pharma Ltd back in 2018 with 40 patients and completed its Phase 1 stage successfully. Since then, 18376 studies have been accomplished globally."

Answered by AI

Are there still opportunities to take part in this experiment?

"The details available on clinicaltrials.gov suggest that this trial is not currently accepting new patients, with the initial posting occurring on June 8th 2021 and the most recent update having been made on May 11th 2022. However, there are 34 other trials which are still actively seeking volunteers."

Answered by AI

Who else is applying?

What state do they live in?
Florida
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
Wendy Lee 2021. "The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04831047.
~30 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top